Please assess the completion status of the following clinical trial:

Trial Title: FactOr XIa inhibiTion for the pRevention of venOus Thromboembolism in Patients Undergoing Total Knee Arthroplasty

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 8.0

Eligibility Criteria:
Inclusion Criteria:~* Patients aged ≥18 years and undergoing elective primary, unilateral Total Knee Arthroplasty (TKA)~* Women of non-childbearing potential~Exclusion Criteria:~* High risk for clinically significant bleeding~* Prior deep vein thrombosis~* Body weight above 135 kg~* Creatinine clearance below 60 ml/min~* Recent (\<6 months) myocardial infarction or ischemic stroke~* Contraindication listed in the local label of the comparator treatments~* Requirement for full dose anticoagulation or dual antiplatelet therapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Enoxaparin (Type: ACTIVE_COMPARATOR): Adult patients who underwent Total Knee Arthroplasty (TKA) surgery and received enoxaparin for at least 10 days until venography was performed.
- Apixaban (Type: ACTIVE_COMPARATOR): Adult patients who underwent Total Knee Arthroplasty (TKA) surgery and received apixaban for at least 10 days until venography was performed.
- BAY1213790 0.3 mg/kg (post-surgery) (Type: EXPERIMENTAL): Adult patients who underwent Total Knee Arthroplasty (TKA) surgery and received 0.3 mg BAY1213790 once post-surgery.
- BAY1213790 0.6 mg/kg (post-surgery) (Type: EXPERIMENTAL): Adult patients who underwent Total Knee Arthroplasty (TKA) surgery and received 0.6 mg BAY1213790 once post-surgery.
- BAY1213790 1.2 mg/kg (post-surgery) (Type: EXPERIMENTAL): Adult patients who underwent Total Knee Arthroplasty (TKA) surgery and received 1.2 mg BAY1213790 once post-surgery.
- BAY1213790 1.8 mg/kg (post-surgery) (Type: EXPERIMENTAL): Adult patients who underwent Total Knee Arthroplasty (TKA) surgery and received 1.8 mg BAY1213790 once post-surgery.
- BAY1213790 0.3 mg/kg (pre-surgery) (Type: EXPERIMENTAL): Adult patients who underwent Total Knee Arthroplasty (TKA) surgery and received 0.3 mg BAY1213790 once pre-surgery.
- BAY1213790 1.8 mg/kg (pre-surgery) (Type: EXPERIMENTAL): Adult patients who underwent Total Knee Arthroplasty (TKA) surgery and received 1.8 mg BAY1213790 once pre-surgery.

Based on this trial design, predict the completion outcome and termination type (if applicable).